RE: Brilliant End of Year report !!! GO HEMO GO30 Apr 2026 16:21
Hemogenyx Pharmaceuticals enters 2026 with a clinical trial that is demonstrably active and successful to date and will move forward definitively in the coming months. There is much work ahead, and the risks inherent to early-stage oncology drug development remain real. But the trajectory of 2025 is one that, in my view, justifies confidence in the strategy, in the team, and in the potential of HG-CT-1 to change the outlook for patients with relapsed and refractory AML.